Trial
NCT04633447
A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Giant Cell Arteritis
Intervention
Guselkumab
Why stopped
The study primary endpoint was not met
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-01